Predict your next investment

Corporation
boai-nky.com

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Partners & Customers

1

About NKY PHARMA

NKY PHARMA (新开源) (SZ: 300109) develops and manufactures polyvinylpyrrolidone (PVP) series products in China.

NKY PHARMA Headquarter Location

Wenhua Road No.1888 Noai County

Jiaozuo, Henan,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest NKY PHARMA News

2020 Edition Report with Impact of COVID-19 on Cyclohexylpyrrolidone Market BASF, NKY PHARMA, Ashland and Hangzhou Ocean Chemical

Oct 20, 2021

Key Topics in this News Article: News Snapshot: 2020 Edition Report with Impact of COVID-19 on Cyclohexylpyrrolidone Market BASF, NKY PHARMA, Ashland and Hangzhou Ocean Chemical Market.Biz Leading Research Firm has added latest report with Impact of COVID-19 on the Global Cyclohexylpyrrolidone Market by Manufacturers, Regions, Type and Application, Forecast to 2026. Global Cyclohexylpyrrolidone Market Report 2020-2026 The report titled Cyclohexylpyrrolidone Market gives a proper understanding of Chemicals and Materials industry. Furthermore it also cover-up forecast and analysis for market on the global and regional level. The report analyses market on basis of its attractiveness and investment feasibility. It also presents proper description of every section and emerging...

NKY PHARMA Investments

2 Investments

NKY PHARMA has made 2 investments. Their latest investment was in HuaDao CAR-Tcell as part of their Series B on July 7, 2019.

CBI Logo

NKY PHARMA Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/27/2019

Series B

HuaDao CAR-Tcell

$11.62M

Yes

3

4/4/2019

Corporate Minority

Subscribe to see more

Subscribe to see more

10

Date

7/27/2019

4/4/2019

Round

Series B

Corporate Minority

Company

HuaDao CAR-Tcell

Subscribe to see more

Amount

$11.62M

New?

Yes

Subscribe to see more

Co-Investors

Sources

3

10

NKY PHARMA Portfolio Exits

1 Portfolio Exit

NKY PHARMA has 1 portfolio exit. Their latest portfolio exit was BioVision on August 02, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/2/2021

Acquired

$99M

5

Date

8/2/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

5

NKY PHARMA Acquisitions

1 Acquisition

NKY PHARMA acquired 1 company. Their latest acquisition was BioVision on December 12, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/12/2017

$99M

Corporate Majority

1

Date

12/12/2017

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Corporate Majority

Sources

1

NKY PHARMA Partners & Customers

1 Partners and customers

NKY PHARMA has 1 strategic partners and customers. NKY PHARMA recently partnered with Abcam on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/28/2021

Vendor

United Kingdom

China’s Boai NKY Soars on Deal With UK’s Abcam to Supply Customized Reagents

Oct. 28 -- Shares in Boai NKY surged as much as 11 percent today after the Chinese pharmaceutics firm said it has signed a five-year deal with the UK 's life science research tools supplier Abcam to provide it with biological reagent raw materials for its in vitro diagnostic products as well as support in their commercialization .

1

Date

10/28/2021

Type

Vendor

Business Partner

Country

United Kingdom

News Snippet

China’s Boai NKY Soars on Deal With UK’s Abcam to Supply Customized Reagents

Oct. 28 -- Shares in Boai NKY surged as much as 11 percent today after the Chinese pharmaceutics firm said it has signed a five-year deal with the UK 's life science research tools supplier Abcam to provide it with biological reagent raw materials for its in vitro diagnostic products as well as support in their commercialization .

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.